Takeda Global R&D Asia, Pte. Ltd. (TGRD) has opened Takeda Shanghai Development Center (TSDC), based within Takeda (China) Holdings Co., Ltd. (TCH), which is a wholly owned subsidiary of Takeda Pharmaceutical Co.
Dr. Benny Li, head of TSDC, said, “The establishment of TSDC provides a powerful addition to Takeda’s global development infrastructure. The opening of TSDC will extend and enhance the company’s clinical development activities within Asia with a focus on China for General Medicine and across Asia (outside Japan) for Oncology. Through the addition of TSDC’s capabilities, Takeda will continue to conduct high quality clinical trials which will lead to securing regulatory approvals in Asia.”
TSDC expands Takeda’s business in China through TCH’s wholly owned subsidiaries, Takeda China in Taizhou, which provides marketing and sales, and Tianjin Takeda, which is responsible for manufacturing. TSDC aims to drive the company’s growth plans in China and in the broader Asian region.
Within Asia, excluding Japan, TGRD oversees drug development in Singapore and Millennium oversees oncology through The Takeda Oncology Co. in Cambridge, MA, both wholly owned subsidiaries of Takeda.